Cronos Group Inc.

NasdaqGM:CRON Rapport sur les actions

Capitalisation boursière : US$987.6m

Cronos Group Croissance future

Future contrôle des critères 3/6

Cronos Group devrait augmenter ses bénéfices et ses revenus de 35.2% et de 5% par an respectivement, tandis que le BPA devrait croître de croître de 37.2% par an.

Informations clés

35.2%

Taux de croissance des bénéfices

37.22%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices14.4%
Taux de croissance des recettes5.0%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour12 May 2026

Mises à jour récentes de la croissance future

Recent updates

Seeking Alpha • May 13

Cronos: Excellent M&A And Favorable Valuation Make This A Buy (Upgrade)

Summary Cronos Group Inc. reported Q1 '26 revenue up 40% to $45 million, exceeding estimates. Despite strong top-line growth, CRON posted a small operating loss of $1.8 million, with net income driven by interest and FX gains. CapEx dropped sharply by 87% year-over-year to $1.9 million, reflecting tighter capital discipline. The acquisition of CanAdelaar will be a game changer for the company's European expansion, as it is extremely strong in both sales and production. Read the full article on Seeking Alpha
Seeking Alpha • Mar 06

Cronos Reports Improved Q4-2024 Financials With Revenues From GrowCo

Summary Cronos reported 27% increase in revenues YOY for Q4-2024. The company is now reporting revenues from its 50% ownership of GrowCo. The company reported increasing profits and free cash flow for the quarter. Cronos’ stock price is up 4.6% over the last twelve months. I rate the company as a Hold for now due to sector weakness. Read the full article on Seeking Alpha
Seeking Alpha • Dec 05

Cronos Group Is Probably Undervalued As Liquidity Swells

Summary CRON's financials show strong liquidity with a sequential increase in cash and cash equivalents, no debt, and positive free cash flow. Despite unprofitability, CRON's assets dwarf liabilities, and it trades at a price-to-book value of 0.71x. CRON's fiscal 2024 third-quarter revenue growth was driven by a 38.1% revenue increase and expanding international operations. The stock's near-term performance hinges on pending cannabis policy changes. Read the full article on Seeking Alpha
Seeking Alpha • Aug 20

Buy Cronos Stock Before It Surges Higher

Summary Initiating coverage on Cronos stock with a "Strong Buy" rating. Cannabis industry tailwinds, conservative growth approach, and geographic expansion support Cronos' growth acceleration and EBITDA margin improvement. A strong cash buffer of $848 million coupled with a zero-debt balance sheet provides flexibility for organic and acquisition-driven growth. Read the full article on Seeking Alpha
Seeking Alpha • Jun 17

Cronos Group: An Intriguing Value Opportunity

Summary Cronos Group Inc. operates in Canada's recreational market and focuses on medicinal cannabis in lucrative markets like Germany and the U.K. The company is experiencing rapid revenue growth in Canada and Israel, with plans to enter new markets in the near future. Despite facing risks related to regulations and profitability, Cronos Group's low valuation makes it an attractive investment opportunity for long-term growth. Read the full article on Seeking Alpha
Seeking Alpha • Mar 04

Cronos Stock: Attractive Now With Cannabis Legalization In Germany

Summary Cronos Group's Q4 and FY23 results were disappointing, with missed earnings and revenue targets. Cronos has a strong cash position and potential for cost savings, but has yet to decide how to allocate its funds. The German market could be an important growth engine for CRON and contribute to exceeding estimates. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Cronos Group: Flush With Cash And Trading Below Book Value

Summary Cronos Group has a cash position of $840 million, which is over 100% of its market cap, and zero debt. The company is trading at a discount to book value, with a potential 36% upside if the stock trades in line with book value. Cronos Group's operational losses are a factor in the current discount, but the company has seen improvements in revenue and gross profit. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Cronos Group GAAP EPS of -$0.05 beats by $0.01, revenue of $23.1M misses by $5.25M

Cronos Group press release (NASDAQ:CRON): Q2 GAAP EPS of -$0.05 beats by $0.01. Revenue of $23.1M (+47.9% Y/Y) misses by $5.25M. The increase year-over-year was primarily driven by an increase in net revenue in the Rest of World (“ROW”) segment driven by growth in the Israeli medical market and the Canadian adult-use market. Israel net revenue increased by 212% year-over-year to $7.2 million in Q2 2022. Shares -2% PM.
Seeking Alpha • Aug 01

Cronos Group: Too Much Cash, Too Soon - Making The Bear Case

Cronos was the first "pot stock" to list on the Nasdaq. The company has a strong cash position of ~$1bn, but losses in FY21 were $395m. Net loss in Q122 was a more modest $32.6m, while revenues were $25m. The issue is that Cronos has few options to deploy funds successfully in a market that remains largely on hold owing to US reluctance to legalise marijuana at the federal level. As such, I can see Cronos' market cap valuation shrinking at the same pace as its funds. Meanwhile, lead investor Altria could exercise an option and increase its ownership >50%. Investment Thesis Most listed companies involved in the business of cannabis cultivation and distribution, whether for recreational or medicinal purposes, trading on the Nasdaq, have seen their share prices nosedive over the past 12 months, and Cronos Group (CRON) is no exception. The Toronto, Canada based company was the first "Pot Stock" to uplist from the Toronto stock exchange (TSX) to the Nasdaq, in March 2018. Early investors would have been delighted with the initial rise in the company' stock price, from ~$7 shortly after the uplisting, to a "high" of nearly $22 in February 2019, but sadly, the gains were short-lived. Barring a brief spike to $10 in January 2021, it has been all downhill for the stock price, which currently trades at a value of $3.15 - down 58% across the past 12 months. Share price performance of Canadian Cannabis companies - past 12 months. (TradingView) As we can see below, rival Canada based cannabis stocks Tilray (TLRY), SNDL (SNDL), Aurora Cannabis (ACB), and Canopy Growth (CGC) have fared even worse. Of these companies, Aurora and Sundial Growers are relative minnow, with market caps of $320m and $535m respectively, Canopy Growth and Cronos are both valued ~$1.2bn, and Tilray is the largest, with a market cap of $1.6bn. Whilst Cronos, Canopy and Tilray boast impressively high cash positions of ~$1bn, $1.4bn, and $803m, the trouble is the companies are reluctant to deploy capital when the market opportunity is so small, and that is chiefly down to the US' refusal to legalise marijuana at the Federal level. A statement in Cronos 2021 10-K submission to the SEC explains: Though a number of states in the U.S. have authorized the cultivation, distribution or possession of U.S. Schedule I cannabis and U.S. Schedule I cannabis containing products to various degrees and subject to various requirements or conditions, U.S. Schedule I cannabis continues to be a Schedule I controlled substance under the CSA. Therefore, the cultivation, manufacture, distribution and possession of U.S. Schedule I cannabis violates federal law in the U.S. unless a U.S. federal agency, such as the DEA, grants a registration for a specific activity, such as research, with U.S. Schedule I cannabis. Cronos Group's Portfolio of Brands. (Cronos investor presentation) The US does permit trade in hemp related products, and as we can see above, Cronos is able to sell its Spinach cannabis brand in Canada, for mainstream adult use thanks to Canada's legalisation of marijuana, and also sells cannabis products for "Wellness" i.e. medicinal use in Australia, Canada, Germany and Israel, and 2 hemp-derived product portfolios in the US, under the Lord Jones and Happy Dance brands. These products don't generate strong revenue streams however - Cronos earned just $25m of revenues in Q122 - which is admittedly up 123% year-on-year - but posted a loss of $32.6m, and earned just $2.3m of revenues from the US. In FY21, 3 major customers - Ontario Cannabis Retail Corporation, Société Québécoise du Cannabis (the "SQDC"), and Alberta Gaming, Liquor and Cannabis Commission - accounted for 26%, 15%, and 15% of the company's revenues of $74.4m. The company's net loss in 2021 was $395.6m. With >600 employees on its payroll, and markets stubbornly refusing to open up, with only limited opportunities internationally in countries authorising cannabis for medicinal use, it's easy to make the bear case for Cronos, given its funds look likely to be exhausted by the end of 2023 at the current burn rate. The only thing likely to save the company is if the US legalises marijuana at the federal level - it is already decriminalised, but that is of no use to companies attempting to ship a schedule I product - defined by the FDA and DEA as having "no therapeutic value" meaning it "therefore cannot be lawfully possessed or prescribed". With all that said, however, in the event that the US does change the classification of marijuana, shareholders in companies like Cronos are likely to realise substantial triple digit gains, positioned as they are to capitalise on any positive developments, and these companies are trading at historical lows. In the rest of this post, I will take a closer look at the situation that Cronos currently finds itself in, and try to discuss whether there is a rewarding opportunity in investing in Cronos stock at a historically low price. Recent Developments in US There are many and persuasive reasons why the US may want to decriminalise cannabis, and these were discussed at a Senate Judiciary Committee Subcommittee on Criminal Justice and Counterterrorism hearing as recently as last week. The Cannabis Administration and Opportunity Act was also introduced by Senate Majority Leader Chuck Schumer last week, which, if passed, would deschedule marijuana as a Schedule I controlled substance. Senator Cory Booker chaired the discussion, highlighting issues such as social injustice, and the amount of police time that may be wasted on hunting down cannabis smokers - he told the senate that in 2019, there were more arrests for cannabis than for all violent crimes combined. Booker also noted that 91% of Americans are in favour of medical marijuana, and 68% support adult use. Despite some persuasive arguments, the "COAC" is unlikely to become because, apparently, it is viewed as too far reaching, and faces strong Republican opposition, whilst President Biden is not thought to favour legalisation at the federal level, preferring an "incremental" approach. The COAC certainly seems to represent praiseworthy progress, but it would be a stretch to claim that it is going to benefit a company like Cronos, firstly because it is unlikely to be passed, and secondly because its main thrust is towards providing social justice, rather than commercial opportunities. COAC may represent progress, but probably not fast enough to stem the flow of losses at Cronos. The Altria Question Meanwhile, Cronos reveals in its 2021 10-K submission that it is ~42% owned by Altria (MO), which made a $1.8bn investment into Cronos back in 2018. Altria is a $79bn market cap holding company, which engages in the manufacture and sale of cigarettes in the United States, and clearly the company saw an opportunity in the cannabis market that it sought to exploit by investing in Cronos. Altria also has the option to increase its stake in Cronos above 50%, at which point the company would effectively own Cronos and have the right to appoint an entirely new board, sell the business, or sell a significant amount of its shares in Cronos, resulting in further share price losses or issue more shares, resulting in investor dilution. Altria and Cronos initially felt there may have been an opportunity in the cannabis vaping market, but no such opportunity has arisen (to the best of my knowledge) and it's tempting to wonder if the much larger Altria intends to cut its losses in Cronos. As such, investors believing that it is only a matter of time before Cronos is in a position to exploit changes in cannabis legislation may be disappointed. Conclusion - Cronos' Bet On Cannabis Markets May Have Come Too Early Cronos' current business would actually look reasonably well organised and successful, based on its differentiated product offering, tailored to suit different markets, most notably Israel and Canada, were it not for the outrageous - for a company of its size - cash burn and meagre return of just $25m in Q122.
Seeking Alpha • May 11

Cronos Group: High Hurdles

Cronos Group is starting to make progress towards building a business warranting the original big Altria investment. The company is still reporting massive EBITDA losses for a business with quarterly revenues of just $25 million. The stock isn't appealing until Cronos leaps the large loss hurdle and finally invests the $1 billion cash balance in productive cannabis assets.
Seeking Alpha • Mar 01

Cronos Earnings: Cannabis Stock With 65% Net Cash And 51% Revenue Growth

After a long delay, Cronos releases both its third quarter and fourth quarter earnings results. Cronos Group's revenues grew 51%, but the adjusted EBITDA loss was more than revenues. Cronos is investing heavily in R&D, specifically, using synthetic biology to produce expensive cannabinoid compounds. CRON stock trades at a premium to Canadian peers, but that looks justified on account of the more rapid growth rate.
Seeking Alpha • Feb 22

Cronos Group Late-Filed Q3-2021 Earnings Show Revenues From Synthetic Cannabinoids

Cronos Group delayed filing of Q3-2021 earnings due to a revision and audit of Q2 reports. Cronos Group beat revenue (+$2.212 million) and EPS (+0.32) consensus on its Q3-2021 report. Revenues are increasing Cronos Group and it currently has synthetic cannabinoid products to market. CRON stock has been on a downtrend along with other cannabis stocks. I rate CRON as a hold and recommend investors watch for a new cannabis stock rally to emerge.
Seeking Alpha • Jan 22

Cronos Group: Still No Reason To Own

Cronos Group still hasn't launched a meaningful business. The Canadian cannabis LP still hasn't filed Q3'21 results. The stock isn't even investable with a $1.1 billion cash position due to massive ongoing EBITDA losses.
Seeking Alpha • Nov 08

Cronos Group Strategic Investor Altria May Be About To Buy The Balance

Altria owns 42% of Cronos Group. Its warrants to take a majority stake are way out of the money and approaching expiration in early 2023. Cronos Group has an enterprise value of just $900 million and would not have a material impact on Altria's financials. Buying the balance of Cronos Group would fit strategically with Altria. The lack of a scheduled conference call ahead of a filing deadline for Q3 financials points to a potential imminent bid.
Seeking Alpha • Aug 30

After Cronos Finally Invests In U.S. Cannabis, Is The Stock A Buy?

CRON is a Canadian licensed producer of cannabis. How much did it pay for PharmaCann? I give my estimate for the valuation that it paid for its investment in the US cannabis operator PharmaCann. CRON trades at a huge premium to Canadian peers like Canopy Growth and Tilray, but I explain why the premium may be warranted. Would Altria still invest in CRON if it made its investment today? I analyze the company's financials and investment prospects as compared to US peers.
Seeking Alpha • Jul 12

Is Cronos Stock Worth Buying? Probably, But Patience Remains A Requirement

Cronos has taken a "slow and steady wins the race" approach to cannabis, with an obvious eye on a fully legalized American market. The case is slowly (and unevenly) playing out, with fermentation efforts progressing and the PharmaCann deal providing a first step into the U.S. At $8, CRON still looks attractive from a long-term perspective, but a key word there is "long-term."

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:CRON - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20282215868712
12/31/20272193946613
12/31/20261923052434
3/31/2026160-22639N/A
12/31/2025147-9026N/A
9/30/202513236-622N/A
6/30/202513018-920N/A
3/31/202512549-819N/A
12/31/202411841619N/A
9/30/2024111-481728N/A
6/30/2024102-571116N/A
3/31/202493-54-23N/A
12/31/202387-70-46-43N/A
9/30/202385-101-86-84N/A
6/30/202381-133-101-97N/A
3/31/202384-145-108-103N/A
12/31/202287-155-94-89N/A
9/30/202291-213-105-101N/A
6/30/202291-102-124-119N/A
3/31/202285-263-147-141N/A
12/31/202165-127-166-154N/A
9/30/202166-373-179-156N/A
6/30/202157-381-181-153N/A
3/31/202151-310-188-153N/A
12/31/202047-72-180-145N/A
9/30/202037101-185-160N/A
6/30/202031636-186-152N/A
3/31/202029929-192-155N/A
12/31/2019241,167N/A-131N/A
9/30/2019211,089N/A-59N/A
6/30/201918479N/A-49N/A
3/31/201913293N/A-11N/A
12/31/201812-21N/A-8N/A
9/30/20189-8N/A-28N/A
6/30/20187-1N/A-16N/A
3/31/20185-2N/A-13N/A
12/31/20173-1N/A-4N/A
9/30/201741N/A-4N/A
6/30/201720N/A-8N/A
3/31/20171-1N/A-6N/A
12/31/20160-1N/A-5N/A
9/30/201620N/A-3N/A
6/30/201620N/A-2N/A
3/31/201631N/A-1N/A
12/31/201520N/A-1N/A
9/30/20150-4N/A-2N/A
6/30/2015-1-4N/A-2N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CRON devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3.5% ).

Bénéfices vs marché: CRON devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: CRON devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CRON ( 5% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CRON ( 5% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CRON devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/18 19:01
Cours de l'action en fin de journée2026/05/15 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Cronos Group Inc. est couverte par 16 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein